+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Urinary N-Acetyl-β- D-Glucosaminidase and β 2-Microglobulin Excretion in Primary Nephrotic Children

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Enzymuria and low molecular weight proteinuria reflect tubular damage and dysfunction, respectively. We examined urinary N-acetyl-β-. D-glucosamini-dase (U-NAG) and β<sub>2</sub>-microglobulin (U-β<sub>2</sub>M) excretion in 17 steroid-resistant and 39 steroid-sensitive children with nephrotic syndrome whose glomerular filtration rates were within the normal range. Fourteen healthy children were taken as controls. U-NAG and U-β<sub>2</sub>M levels did not show a difference between the steroid-resistant and steroid-sensitive groups but were significantly higher in the nephrotic groups compared to the controls (p < 0.0001 and p < 0.01, respectively). In the steroid-sensitive group, U-NAG levels were significantly higher in patients in the relapse phase than in those in remission (p < 0.0001). This finding was also valid for U-β<sub>2</sub>M excretion, but reached significance only for patients in remission who did not receive steroids (p < 0.01). There was a positive correlation between proteinuria and U-NAG and Uβ<sub>2</sub>M excretion in all patients (r<sub>s</sub> = 0.69, p < 0.001 and r<sub>s</sub> = 0.39, p < 0.001, respectively). In conclusion, massive glomerular proteinuria may cause a marked U-NAG excretion and a moderate urinary U-β<sub>2</sub>M elevation independent of primary renal disease.

          Related collections

          Author and article information

          S. Karger AG
          24 December 2008
          : 74
          : 2
          : 401-404
          aPediatric Nephrology Unit, Department of Pediatrics, bCentral Research Laboratory and cDepartment of Pathology, Cerrahpașa Faculty of Medicine, University of Istanbul, Turkey
          189442 Nephron 1996;74:401–404
          © 1996 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 4
          Original Paper


          Comment on this article